The successful Phase III data de-risks the sNDA pathway for rezafungin’s expanded use and could drive revaluation of CorMedix’s commercial potential. Traders should monitor the pre-NDA discussion with the FDA and upcoming detailed data disclosures, which may further validate the benefit-risk profile ahead of regulatory submission.
Price Chart
Executive Summary
CorMedix announced positive Phase III topline results from the ReSPECT trial, showing that rezafungin met the primary endpoint of non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 for patients undergoing allogeneic HSCT. The drug demonstrated a favorable safety profile, particularly in reduced toxicity-related discontinuations and drug-drug interactions, supporting a potential sNDA submission in 2H26 for expanded prophylactic use.
Key Facts
- ReSPECT Phase III trial met primary FDA/EMA endpoint: non-inferiority in fungal-free survival at Day 90 (60.7% for rezafungin vs. 59.0% for standard regimen).
- Rezafungin showed favorable secondary outcomes in safety, including lower rates of treatment discontinuation due to adverse events and fewer drug-drug interactions.
- sNDA submission to FDA expected in 2H26, following a pre-NDA meeting.
- Rezafungin is already approved for candidemia and invasive candidiasis; this data supports expansion into prophylaxis, a potential $2B+ US market.
- Mundipharma sponsored the trial and holds commercial rights outside the U.S.; Melinta (CorMedix subsidiary) handles U.S. distribution.
Financial Impact
Potential $2+ billion U.S. market opportunity for prophylactic use, based on company estimates.
Risk Factors
- Forward-looking market size estimates are speculative and subject to regulatory approval, adoption, and competition.
- Topline data may be revised as full dataset is analyzed.
- Commercial success depends on payer reimbursement and physician uptake despite current approval for treatment indications.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281520 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $8.14 $7.83 | ▼ −3.87% | ▼ −2.12% | $7.19 (−11.67%) |
Aug 13, 2026 7w ago | Press Release | $8.14 $7.83 | ▼ −3.87% | ▼ −2.12% | $7.19 (−11.67%) |
Jul 1, 2026 13w ago | 8-K | $8.47 $7.19 | ▼ −15.11% | ▼ −12.93% | $7.19 (−15.11%) |
Jun 12, 2026 16w ago | Institutional Cluster | $8.74 $8.40 | ▼ −3.89% | ▼ −5.67% | $7.19 (−17.73%) |
Jun 8, 2026 16w ago | 8-K | $8.54 $8.79 | ▲ +2.93% | ▲ +1.30% | $7.19 (−15.81%) |
Jun 8, 2026 16w ago | Press Release | $8.54 $8.79 | ▲ +2.93% | ▲ +1.30% | $7.19 (−15.81%) |
May 14, 2026 20w ago | 8-K | $7.93 $8.74 | ▲ +10.21% | ▲ +11.07% | $7.19 (−9.33%) |
May 14, 2026 20w ago | Press Release | $7.93 $8.74 | ▲ +10.21% | ▲ +11.07% | $7.19 (−9.33%) |
Apr 27, 2026 22w ago | 8-K | $7.82 $8.27 | ▲ +5.75% | ▲ +0.80% | $7.19 (−8.06%) |
Apr 27, 2026 22w ago | Press Release | $7.82 $8.27 | ▲ +5.75% | ▲ +0.80% | $7.19 (−8.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access